āĻāĻ āĻāĻĒāĻŋāĻ¸ā§āĻĄ āĻ¸āĻŽā§āĻŦāĻ¨ā§āĻ§ā§
đī¸ In this episode we discuss:
01:06 The founding story of Retina AI
03:56 Why ophthalmology is uniquely suited for AI solutions
06:27 Recent Series B funding and what it means for the company
08:31 How AI integrates into real-world clinical workflows
12:04 AI alerts and notifications for clinical decision support
16:36 Working with pharmaceutical companies on clinical trials
19:15 Predicting disease progression for untreated patients
25:42 The transition from traditional AI to newer approaches
29:28 Expanding beyond eye care with the Ikerian rebrand
32:06 Using the eye as a window to detect other diseases
37:44 How physicians have responded to AI diagnostic tools
41:09 Predictions for AI in healthcare and eye care by 2028
āĻāĻāĻ°ā§āĻāĻŋ
āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°
āĻĒā§āĻ°āĻ¤āĻŋāĻ˛āĻŋāĻĒāĻŋ 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
āĻ āĻ¤ā§āĻ¤ā§āĻ° āĻāĻĒāĻŋāĻ¸ā§āĻĄāĻā§āĻ˛āĻŋ āĻ āĻ¨ā§āĻ¸āĻ¨ā§āĻ§āĻžāĻ¨ āĻāĻ°ā§āĻ¨
The Harry Glorikian Show āĻāĻ° āĻ
āĻ¤ā§āĻ¤ā§āĻ° āĻāĻĒāĻŋāĻ¸ā§āĻĄāĻā§āĻ˛āĻŋ āĻ
āĻ¨ā§āĻ¸āĻ¨ā§āĻ§āĻžāĻ¨ āĻāĻ°ā§āĻ¨āĨ¤
āĻāĻ āĻĒāĻĄāĻāĻžāĻ¸ā§āĻā§āĻ° āĻ āĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¯ āĻĒāĻ°ā§āĻŦāĻā§āĻ˛āĻŋā§ˇ
Investors and companies in the life science industry have been betting a lot of money over the last few years on a single idea: that computation will help us get a lot better at developing new drugs. But the word âcomputationâ covers a pretty broad range of techniques. And the reason that there areâĻ
If you learned that radiologists looking at CT scans for the traditional signs of coronary artery disease catch only 20 percent of the people who actually have a high risk of a heart attack, and if you learned that thereâs a new AI-based test that can catch subtle signs of inflammation in the otherâĻ
One of the most amazing successes in the battle against cancer over the last two decades has been the introduction of antibody drugs that harness the bodyâs own immune system to kill tumor cells. Finding those drugs may sound like a biology problem rather than a machine learning or a big-data problâĻ
If you look back at all the health-tech and drug development companies Harry has hosted on the show, an interesting pattern starts to emerge: a very large number of those companies have gone on to enormous growth and success in their markets. It could be that being on the podcast is like a catapultâĻ
Generative AI is going to change how we do things across the entire economy, including the fields Harry covers on the show, namely healthcare delivery, drug discovery, and drug development. But weâre still just starting to figure out exactly how itâs going to change things. For example, AI is alreaâĻ
āĻĻāĻžāĻŦāĻŋ āĻĒāĻ°āĻŋāĻ¤ā§āĻ¯āĻžāĻ: āĻāĻ āĻĒā§āĻˇā§āĻ āĻžāĻ¯āĻŧ āĻāĻŽā§āĻŦā§āĻĄ āĻāĻ°āĻž āĻĒāĻĄāĻāĻžāĻ¸ā§āĻ āĻāĻŦāĻ āĻāĻ°ā§āĻāĻāĻ¯āĻŧāĻžāĻ°ā§āĻ Harry Glorikian āĻĨā§āĻā§ āĻāĻ¸ā§āĻā§, āĻ¯āĻž āĻāĻ° āĻŽāĻžāĻ˛āĻŋāĻā§āĻ° āĻ¸āĻŽā§āĻĒāĻ¤ā§āĻ¤āĻŋ āĻāĻŦāĻ Listen Notes, Inc āĻĻā§āĻŦāĻžāĻ°āĻž āĻ
āĻ¨ā§āĻŽā§āĻĻāĻŋāĻ¤ āĻŦāĻž āĻ
āĻ¨ā§āĻŽā§āĻĻāĻŋāĻ¤ āĻ¨āĻ¯āĻŧā§ˇ
āĻ¸āĻŽā§āĻĒāĻžāĻĻāĻ¨āĻž
āĻĒāĻĄāĻāĻžāĻ¸ā§āĻ āĻĄā§āĻāĻžāĻŦā§āĻ¸ āĻāĻĒ āĻā§ āĻĄā§āĻ āĻ°āĻžāĻāĻ¤ā§ āĻ¸āĻžāĻšāĻžāĻ¯ā§āĻ¯ āĻāĻ°āĻžāĻ° āĻāĻ¨ā§āĻ¯ āĻāĻĒāĻ¨āĻžāĻā§ āĻ§āĻ¨ā§āĻ¯āĻŦāĻžāĻĻāĨ¤
